Subscribe and receive the latest updates on trends, data, events and more.
Join 57,000+ members of the natural products community.
EFSA publishes its much-anticipated risk assessment on caffeine.
January 16, 2015
1 Min Read
Single doses of caffeine up to 200 mg and daily intakes of up to 400 mg do not raise safety concerns for adults in Europe. These are two of the provisional findings of EFSA’s Scientific Opinion on the safety of caffeine from all sources. EFSA is now seeking comments and feedback on the draft document through a public consultation which is open until March 15, 2015.
EFSA is also planning to hold a stakeholder meeting in the first week of March to explain and discuss the draft opinion with interested parties. Details of the meeting will be announced shortly on EFSA’s website.
Other key provisional conclusions include:
Single doses of caffeine up to 200 mg do not raise safety concerns for adults (18 to 65 years) also when consumed less than two hours before intense exercise.
It is unlikely that caffeine interacts adversely with other constituents of “energy drinks”—such as taurine and D-glucurono-γ-lactone—or alcohol.
For pregnant women, caffeine intakes of up to 200 mg a day do not raise safety concerns for the fetus.
For children (3 to 10 years) and adolescents (10 to 18 years), daily intakes of 3 mg per kg of body weight are considered safe.
Single doses of 100 mg may increase sleep latency (the amount of time it takes to fall asleep) and shorten sleeping time in some adults.
You May Also Like
